SCHEMBL25835301

SCHEMBL25835301

CCCC(=O)NCCOCCNC(=O)CCOCCN

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.46
CTSD P07339 1/20 0.39
SLC6A5 Q9Y345 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA4 P22748 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
TLR2 O60603 2/20 0.38
HPGD P15428 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CHRNA1 P02708 1/20 0.37
CHRNG P07510 1/20 0.37
CHRNB1 P11230 1/20 0.37
CHRND Q07001 1/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25835672 0.96 CASP2 (0.48) CASP2CTSDSLC6A5HDAC3HDAC1
SCHEMBL25835891 0.89 CASP2 (0.40) CASP2CTSDSLC6A5TLR2TSHR
SCHEMBL20904578 0.89 CA2 (0.44) HDAC3HDAC1CA12CA1CA2
SCHEMBL26430827 0.89 CA2 (0.44) HDAC3HDAC1CA12CA1CA2
SCHEMBL19594069 0.89 CA2 (0.44) HDAC3HDAC1CA12CA1CA2
SCHEMBL14197469 0.89 CA2 (0.44) HDAC3HDAC1CA12CA1CA2
SCHEMBL14575431 0.89 CA2 (0.44) HDAC3HDAC1CA12CA1CA2
SCHEMBL15704808 0.88 SMN1; SMN2 (0.40) HDAC3HDAC1CA12CA1CA2
SCHEMBL25835310 0.87 SLC6A5 (0.54) CASP2SLC6A5TLR2
SCHEMBL25835296 0.87 SLC6A5 (0.54) CASP2SLC6A5TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 CASP2 4430/4885CTSD 2858/4885SLC6A5 4323/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 CASP2 4432/4885CTSD 2604/4885SLC6A5 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.